{"disease":{"id":"huntington-s-chorea","name":"Huntington's chorea","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"deutetrabenazine","indication_name":"Huntington's chorea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Austedo","generic_name":"DEUTETRABENAZINE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Synaptic vesicular amine transporter","drug_class":"","quality_score":70,"revenue":"1100","mechanism":"Austedo works by binding to the synaptic vesicular amine transporter, reducing the release of dopamine and other neurotransmitters."},{"drug_id":"tetrabenazine","indication_name":"Huntington's chorea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xenazine","generic_name":"TETRABENAZINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Synaptic vesicular amine transporter","drug_class":"Vesicular Monoamine Transporter 2 Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Xenazine works by blocking the reuptake of dopamine and other neurotransmitters into synaptic vesicles, reducing their release and alleviating symptoms of Huntington's chorea."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03575676","title":"Efficacy and Safety of SOM3355 in Huntington's Disease Chorea","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"SOM Innovation Biotech SA","has_results":false},{"nct_id":"NCT04201834","title":"Risperidone for the Treatment of Huntington's Disease Involuntary Movements","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"University of Rochester","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}